Adam Robertson
Chief Scientific Officer Hemispherian
Seminars
Tuesday 5th May 2026
Advancing Targeted DNA Damage Therapy for Glioblastoma – From Preclinical Success to Clinical Trials
10:00 am
- Discussing the rationale behind applying orthotopic xenograft models to empower small molecule development to better treat glioblastoma
- Demonstrating potent anti-tumour activity of this small molecule in multiple glioblastoma models with strong blood-brain barrier penetration and favourable safety in toxicology studies
- Leveraging these preclinical findings to build a strong IND package and begin treating patients with high unmet medical need with the hope of better understanding the translational relevance of these models
